scispace - formally typeset
F

Fanny Chui Fun Ip

Researcher at Hong Kong University of Science and Technology

Publications -  25
Citations -  261

Fanny Chui Fun Ip is an academic researcher from Hong Kong University of Science and Technology. The author has contributed to research in topics: Neuroprotection & Receptor. The author has an hindex of 8, co-authored 25 publications receiving 222 citations.

Papers
More filters
Journal ArticleDOI

Cycloastragenol is a potent telomerase activator in neuronal cells: implications for depression management.

TL;DR: It is demonstrated that CAG stimulates telomerase activity and cell proliferation in human neonatal keratinocytes and rat neuronal cells, and induces CREB activation followed by tert and bcl2 expression, and may have a novel therapeutic role in depression.
Journal ArticleDOI

Highly trans‐Selective Arylation of Achmatowicz Rearrangement Products by Reductive γ‐Deoxygenation and Heck–Matsuda Reaction: Asymmetric Total Synthesis of (−)‐Musellarins A–C and Their Analogues

TL;DR: A new two-step trans arylation of AR products to access 2,6-trans-dihydropyranones is reported, demonstrated in the first asymmetric total synthesis of (-)-musellarins A-C and 12 analogues in 11-12 steps.
Journal ArticleDOI

Coronin 6 Regulates Acetylcholine Receptor Clustering through Modulating Receptor Anchorage to Actin Cytoskeleton

TL;DR: Coronin 6, a newly identified member of the coronin family, is highly enriched at adult NMJs and regulates AChR clustering through modulating the interaction between receptors and the actin cytoskeletal network.
Journal ArticleDOI

Neuroprotective effect of a novel Chinese herbal decoction on cultured neurons and cerebral ischemic rats

TL;DR: PSR is neuroprotective both in vitro and in vivo – it protects cultured neurons against NMDA excitotoxicity, and effectively reduces ischemic injury and neurobehavioral deficit in MCAO rats in both the pre- and post-treatment regimens.
Journal ArticleDOI

Olean-12-eno[2,3-c] [1,2,5]oxadiazol-28-oic acid (OEOA) induces G1 cell cycle arrest and differentiation in human leukemia cell lines.

TL;DR: OEOA significantly reduces cell proliferation without inducing cell death in three types of leukemia cell lines, including K562, HEL and Jurket, and is identified as a novel chemical entity for further development as therapeutics against leukemia.